Search

Your search keyword '"Reyes-Sandoval, Arturo"' showing total 19 results
Start Over Author "Reyes-Sandoval, Arturo" Publisher mdpi ag
19 results on '"Reyes-Sandoval, Arturo"'

7. Chikungunya E2 Protein Produced in E. coli and HEK293-T Cells—Comparison of Their Performances in ELISA

Author

Bagno, Flávia Fonseca, primary, Godói, Lara Carvalho, additional, Figueiredo, Maria Marta, additional, Sérgio, Sarah Aparecida Rodrigues, additional, Moraes, Thaís de Fátima Silva, additional, Salazar, Natália de Castro, additional, Kim, Young Chan, additional, Reyes-Sandoval, Arturo, additional, and da Fonseca, Flávio Guimarães, additional

Published
2020
Full Text
View/download PDF

9. Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines

Author

López-Camacho, César, primary, De Lorenzo, Giuditta, additional, Slon-Campos, Jose Luis, additional, Dowall, Stuart, additional, Abbink, Peter, additional, Larocca, Rafael A., additional, Kim, Young Chan, additional, Poggianella, Monica, additional, Graham, Victoria, additional, Findlay-Wilson, Stephen, additional, Rayner, Emma, additional, Carmichael, Jennifer, additional, Dejnirattisai, Wanwisa, additional, Boyd, Michael, additional, Hewson, Roger, additional, Mongkolsapaya, Juthathip, additional, Screaton, Gavin R., additional, Barouch, Dan H., additional, Burrone, Oscar R., additional, Patel, Arvind H., additional, and Reyes-Sandoval, Arturo, additional

Published
2020
Full Text
View/download PDF

13. Development of an E2 ELISA Methodology to Assess Chikungunya Seroprevalence in Patients from an Endemic Region of Mexico

Author

Kim, Young Chan, primary, López-Camacho, César, additional, Garcia-Larragoiti, Nallely, additional, Cano-Mendez, Alan, additional, Hernandez-Flores, Karina Guadalupe, additional, Domínguez-Alemán, Carlos Alonso, additional, Antonieta Mar, Maria, additional, Vivanco-Cid, Héctor, additional, Viveros-Sandoval, Martha Eva, additional, and Reyes-Sandoval, Arturo, additional

Published
2019
Full Text
View/download PDF

15. Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria

Author

Cabral-Miranda, Gustavo, primary, Heath, Matthew, additional, Gomes, Ariane, additional, Mohsen, Mona, additional, Montoya-Diaz, Eduardo, additional, Salman, Ahmed, additional, Atcheson, Erwan, additional, Skinner, Murray, additional, Kramer, Matthias, additional, Reyes-Sandoval, Arturo, additional, and Bachmann, Martin, additional

Published
2017
Full Text
View/download PDF

16. Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax

Author

Cabral-Miranda, Gustavo, primary, Heath, Matthew, additional, Mohsen, Mona, additional, Gomes, Ariane, additional, Engeroff, Paul, additional, Flaxman, Amy, additional, Leoratti, Fabiana, additional, El-Turabi, Aadil, additional, Reyes-Sandoval, Arturo, additional, Skinner, Murray, additional, Kramer, Matthias, additional, and Bachmann, Martin, additional

Published
2017
Full Text
View/download PDF

17. Chikungunya Virus: Priority Pathogen or Passing Trend?

Author

Montalvo Zurbia-Flores G, Reyes-Sandoval A, and Kim YC

Abstract

Chikungunya virus (CHIKV) is considered a priority pathogen and a major threat to global health. While CHIKV infections may be asymptomatic, symptomatic patients can develop chikungunya fever (CHIKF) characterized by severe arthralgia which often transitions into incapacitating arthritis that could last for years and lead to significant loss in health-related quality of life. Yet, Chikungunya fever (CHIKF) remains a neglected tropical disease due to its complex epidemiology and the misrepresentation of its incidence and disease burden worldwide. Transmitted to humans by infected Aedes mosquitoes, CHIKV has dramatically expanded its geographic distribution to over 100 countries, causing large-scale outbreaks around the world and putting more than half of the population of the world at risk of infection. More than 50 years have passed since the first CHIKV vaccine was reported to be in development. Despite this, there is no licensed vaccine or antiviral treatments against CHIKV to date. In this review, we highlight the clinical relevance of developing chikungunya vaccines by discussing the poor understanding of long-term disease burden in CHIKV endemic countries, the complexity of CHIKV epidemiological surveillance, and emphasising the impact of the global emergence of CHIKV infections. Additionally, our review focuses on the recent progress of chikungunya vaccines in development, providing insight into the most advanced vaccine candidates in the pipeline and the potential implications of their roll-out.

Published
2023
Full Text
View/download PDF

18. A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease.

Author

Campos RK, Preciado-Llanes L, Azar SR, Lopez-Camacho C, Reyes-Sandoval A, and Rossi SL

Abstract

The mosquito-borne chikungunya virus (CHIKV) has become a major global health problem. Upon infection, chikungunya fever (CHIKF) can result in long-term joint pain and arthritis, and despite intense research, no licensed vaccine for CHIKV is available. We have developed two recombinant chimpanzee adenovirus-vectored vaccines (ChAdOx1) that induce swift and robust anti-CHIKV immune responses with a single dose, without the need for adjuvants or booster vaccines. Here, we report the vaccines' protective efficacies against CHIKV infection in a lethal A129 mouse model. Our results indicate that a single, un-adjuvanted ChAdOx1 Chik or ChAdOx1 Chik ΔCap dose provided complete protection against a lethal virus challenge and prevented CHIKV-associated severe inflammation. These candidate vaccines supported survival equal to the attenuated 181/25 CHIKV reference vaccine but without the vaccine-related side effects, such as weight loss. Vaccination with either ChAdOx1 Chik or ChAdOx1 Chik ΔCap resulted in high titers of neutralizing antibodies that are associated with protection, indicating that the presence of the capsid within the vaccine construct may not be essential to afford protection under the conditions tested. We conclude that both replication-deficient ChAdOx1 Chik vaccines are safe even when used in A129 mice and afford complete protection from a lethal challenge.

Published
2019
Full Text
View/download PDF

19. Microcrystalline Tyrosine (MCT ® ): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.

Author

Cabral-Miranda G, Heath MD, Gomes AC, Mohsen MO, Montoya-Diaz E, Salman AM, Atcheson E, Skinner MA, Kramer MF, Reyes-Sandoval A, and Bachmann MF

Abstract

Microcrystalline Tyrosine (MCT ® ) is a widely used proprietary depot excipient in specific immunotherapy for allergy. In the current study we assessed the potential of MCT to serve as an adjuvant in the development of a vaccine against malaria. To this end, we formulated the circumsporozoite protein (CSP) of P. vivax in MCT and compared the induced immune responses to CSP formulated in PBS or Alum. Both MCT and Alum strongly increased immunogenicity of CSP compared to PBS in both C57BL/6 and BALB/c mice. Challenge studies in mice using a chimeric P. bergei expressing CSP of P. vivax demonstrated clinically improved symptoms of malaria with CSP formulated in both MCT and Alum; protection was, however, more pronounced if CSP was formulated in MCT. Hence, MCT may be an attractive biodegradable adjuvant useful for the development of novel prophylactic vaccines., Competing Interests: M.D.H., M.A.S., M.F.K., G.C.M. are all employees of Allergy Therapeutics Plc or paid by a grant awarded by Allergy Thrapeutics Plc. M.F.B. is involved with different companies developing vaccines including Allergy Thrapeutics Plc. There are no other conflicts of interest.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results